LAMIVUDINE,NEVIRAPINE,ZIDOVUDINE

Lamivudine + Nevirapine + Zidovudine is a combination of three antiretroviral medicines approved by the U.S. Food and Drug Administration for the treatment of HIV-1 infection.

Lamivudine + Nevirapine + Zidovudine is available as a tablet. Lamivudine and Zidovudine belong to the class of medications called nucleoside/nucleotide reverse transcriptase inhibitors. Nevirapine belongs to the class of medication called non-nucleoside reverse transcriptase inhibitors. It is used to treat HIV-1 infection.

Take the Lamivudine + Nevirapine + Zidovudine as advised by your physician. Swallow the tablets whole and intact. This tablet should be taken with food. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the medicine if your doctor advises you to stop.

The common side effects of Lamivudine + Nevirapine + Zidovudine are nausea, diarrhoea, headache, dizziness, cough and difficulty sleeping.

Lamivudine + Nevirapine + Zidovudine is not recommended if you are allergic to this drug or any other active substance or if you are pregnant or breastfeeding women. Inform your physician if you have liver issues, hepatitis infection, kidney diseases, or undergoing dialysis. Tell your physician if you have any active skin conditions such as rash. This tablet can interact with certain medications, potentially affecting their efficacy or increasing the risk of side effects. It's necessary to inform your doctor about all your medications, including prescription, over-the-counter, and herbal supplements, to ensure no potential interactions.

This Lamivudine + Nevirapine + Zidovudine is not advised for patients with anemia (low red blood cells) or neutropenia (low white blood cells). Inform your doctor if you have any liver disease, including hepatitis B or C, kidney disease, or are overweight. The administration of this drug is associated with hematologic toxicity (decrease in blood cells), muscle weakness, liver diseases and infection, and lactic acidosis (acid buildup due to problems in the body's metabolism). This medication is not advised for children less than 35 kg. Lamivudine, Nevirapine, and zidovudine Lamivudine + Nevirapine + Zidovudine may cause decreased fertility in females. Talk to your physician if you have any concerns about fertility.

Follow your doctor's guidance on high-risk activities including unprotected sex and sharing personal items that may contact blood or body fluids, such as toothbrushes, razor blades, and needles. Safe sex practices using condoms are recommended to reduce exposure to semen, blood, or vaginal secretions. If you miss a dose of Lamivudine + Nevirapine + Zidovudine, take your next dose at the scheduled time. Do not double the next dose to compensate for a missed dose.

Micro Labs USA Inc, US Food and Drug Administration,[ Revised on August 2018] [ Accessed on 19th May 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205626s000lbl.pdf Lamivudine, Nevirapine, Zidovudine. South Ruislip, Middlesex: Aurobindo Pharma - Milpharm Ltd. Prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/pepfar/021939PI.pdf [ Accessed on 19th May 2023]. HIV drug resistance database. Available at: https://hivdb.stanford.edu/pages/linksPages/NVP_3TC_AZT_GenericCombination.pdf [ Accessed on 19th May 2023]. KD Tripathi, Essentials of Medical Pharmacology, Antiviral drugs,7th edition, 2013, 806 - 811. Goodman & Gilman's, The Pharmacological Basis of Therapeutics, Antiretroviral agents and treatment of HIV infection, 12th edition, 2011, 1632-1644.